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Abstract
Background: Eight outbreaks of paralytic polio attributable to circulating vaccine-derived poliovirus (cVDPV) have
highlighted the risks associated with oral poliovirus vaccine (OPV) use in areas of low vaccination coverage and poor
hygiene. As the Polio Eradication Initiative enters its final stages, it is important to consider the extent to which these viruses
spread under different conditions, so that appropriate strategies can be devised to prevent or respond to future cVDPV
outbreaks.
Methods and Findings: This paper examines epidemiological (temporal, geographic, age, vaccine history, social group,
ascertainment), and virological (type, genetic diversity, virulence) parameters in order to infer the numbers of individuals
likely to have been infected in each of these cVDPV outbreaks, and in association with single acute flaccid paralysis (AFP)
cases attributable to VDPVs. Although only 114 virologically-confirmed paralytic cases were identified in the eight cVDPV
outbreaks, it is likely that a minimum of hundreds of thousands, and more likely several million individuals were infected
during these events, and that many thousands more have been infected by VDPV lineages within outbreaks which have
escaped detection.
Conclusions: Our estimates of the extent of cVDPV circulation suggest widespread transmission in some countries, as might
be expected from endemic wild poliovirus transmission in these same settings. These methods for inferring extent of
infection will be useful in the context of identifying future surveillance needs, planning for OPV cessation and preparing
outbreak response plans.
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Introduction
Much of the success of the Polio Eradication Initiative (PEI) to
date can be attributed to massive use of oral polio vaccine (OPV),
administered through routine immunisation services and supple-
mentary immunisation activities in the form of National
Immunisation Days (NIDs) and subnational immunisation days
(sNIDs) in over 100 countries since 1988. Though it is a powerful
tool for preventing poliomyelitis, OPV has two disadvantages. In
addition to carrying a low risk of vaccine-associated paralytic
poliomyelitis (VAPP) among vaccinees or their close contacts, it is
now known that vaccine viruses can be serially transmitted
through human hosts, and may revert genetically towards wild-
type transmissibility and virulence.
The degree of genetic change in vaccine-derived polioviruses
(VDPV) is routinely assessed by determining the number of
nucleotide substitutions in the VP1 gene, relative to the sequence
of the Sabin vaccine viruses, and typically occurs at a rate of
approximately 1% per annum[1–4]. A virus is defined as a VDPV if
it has $1% divergence in the VP1 sequence compared to the
corresponding Sabin strain. The prefix c is used to denote
‘‘circulating’’ (two or more clinical cases), and i for VDPV excreted
by immunodeficient individuals[5,6]. The prefix a (for ‘‘ambiguous’’)
is used to describe VDPV isolates from persons with no known
immunodeficiency or environmental isolates whose ultimate source
has not been identified[5].
Eight outbreaks attributable to cVDPV have so far been fully
documented: in Hispaniola, Indonesia, Egypt, Madagascar (62),
Philippines, China and Cambodia, resulting in a total of 114
virologically-confirmed (and an unknown number of undiagnosed
or unreported) cases[1,7–13]. Two further cVDPV outbreaks were
under investigation as this manuscript was submitted, including 5
virologically-confirmed (VC) cases in Myanmar and approximate-
ly 130 VC cases in Nigeria and Niger[14]. Single cases of acute
flaccid paralysis (AFP) attributable to VDPV have been reported
in several other settings[6,7,14–17] and single VDPV isolates have
also been identified in environmental samples and in healthy
contacts of AFP cases[7,14,18–20]
Spread of VDPV infection is likely to be a function of virus
transmissibility, population immunity levels, and other population
characteristics such as density, socio-economic status, sanitation
levels and hygiene-related behaviour, ascertainment efficiency of
infection and/or cases, the nature and scope of response activities,
and chance. Both the transmissibility and virulence (as measured
by the case-to-infection ratio) of VDPVs are difficult to define, as
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importance as the PEI approaches its final stages.
As part of the plan to discontinue OPV after wild poliovirus
(WPV) eradication, there is discussion of vaccine stockpiles, and
response strategies to manage any polio outbreaks in the ‘‘post-
certification’’ era[21,22]. Among potential outbreak threats is the
possibility that VDPV strains may persist after OPV is
discontinued, or as a consequence of the re-introduction of OPV
into susceptible populations later, from residual vaccine stores or
vaccine manufacturers[23]. Outbreak response strategies should
therefore include methods for estimating the likely geographic
spread of VDPV infection prior to and during an outbreak, so that
vaccination and other response activities cover an appropriate
area. Furthermore, stockpiles of OPV, and in particular
monovalent OPV (mOPV), have been proposed for future polio
outbreak response[22]. The risks associated with such interven-
tions include the potential spread of mOPV-derived VDPV in
susceptible populations. Information on the potential spread of
VDPV in different contexts will be helpful for developing policies
to deal with any such eventualities.
There has been little discussion of the geographic spread of
cVDPV outbreak strains, or of the numbers of infections
associated with these and other reported VDPV episodes. In this
paper, we develop lines of argument to infer the extent of VDPV
spread in outbreak populations. We apply the reasoning to data
from three of the largest reported cVDPV outbreaks (Hispaniola,
Indonesia and Egypt) in order to give crude estimates of the
potential numbers of individuals infected with VDPV in each of
these settings. We then summarise findings for five smaller cVDPV
outbreaks (Madagascar (62), Philippines, China and Cambodia),
and discuss individual VDPV isolates, including iVDPV, and their
implications for vaccine-derived virus spread.
Methods
The data used here come from published reports of eight
documented cVDPV outbreaks, shown in table 1. The following
lines of argument are used to infer the total numbers infected in
each episode:
1 Space-time pattern of cases or other isolates
The further apart that cases or (e.g. environmental) isolates are
identified in space and time, then the further and longer the
implied extent and duration of virus circulation. The total
duration of an outbreak, both before and after the initiation of
response activities, is also indicative of the extent of infection
spread.
Given that virus excretion starts within hours or days after
infection, and usually lasts 4–6 weeks[24], the interval between
successive infections is likely to average 2–4 weeks (this interval
will be inversely related to the population density and the
proportion susceptible, since the presence of large numbers of
susceptibles will favour transmission early in the course of the
infection). This implies an estimate of between 13 and 26
‘‘generations’’ of transmission per year per virus lineage, at least
in immunocompetent populations.
2 Population immunity
A low prevalence of immunity to poliovirus infection (i.e.
enteric immunity) is likely to encourage cVDPV emergence and
spread. The degree of ‘‘naturally-induced’’ immunity can be
inferred from the time since the corresponding wild serotype was
eliminated, while vaccine-induced immunity can be inferred
from the type and extent of past vaccination coverage. Vaccine-
induced immunity is complicated however, since not all
vaccinated individuals become immune (or seropositive), re-
sponses differ by type, and some unvaccinated individuals are
immunised by secondary transmission of vaccine virus. Preva-
lence of immunity to type 2 (at least as reflected by seropositivity)
in any age cohort is likely to be equal to or higher than the
proportion who have received three routine doses or two doses
during campaigns. Immunity (seropositivity) to types 1 and 3 is
likely to be lower than the uptake percentages, and to vary
considerably between populations, as there is evidence for per
dose efficacy as low as 10–20% in some parts of India [25–27].
The relationship between vaccination history and seroprevalence
will depend upon environment, crowding and hygiene, and
deserves further attention. Waning of immunity may need to be
considered in future, but is poorly understood.
Table 1. Summary of reported cVDPV outbreaks with corresponding estimated number of infections
Country
Number of reported
cases Type
Date of onset of
index case
Est. duration of
virus circulation
Estimated number of
cVDPV infections References
Hispaniola (pop
{: 16.4
million)
21 VC & 21 PC * 1 July 2000 ,2 years 100,000–200,000 [12,48,49]
Madura, Indonesia
(pop: 3.5 million)
46 VC and 10 PC 1 June 2005 ,2 years 100,000+ [11]
Egypt (pop: 55.8 million) 30 VC 2 1988 ,10 years Several million [1]
Philippines (pop: 75.7
million)
3 VC 1 March 2001 ,3 years 1,000–10,000 [9,62]
Madagascar (pop: 16
million)
4 VC 2 March 2002 ,2.5 years 10,000–50,000 [10]
China (pop: 1.3 billion) 3 VC 1 May 2004 ,1 year 1,000–10,000 [8]
Madagascar (pop: 16
million)
5VC 2 April 2005 ,1.5 years 10,000–50,000 [13]
Cambodia (pop: 14 million) 2 VC 3 Nov 2005 ,2 years 1,000–10,000 [7,14,63]
*VC (virologically-confirmed), PC (polio-compatible)
{approximate population size at the time of the outbreak
doi:10.1371/journal.pone.0003433.t001
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during a cVDPV outbreak is the number susceptible during the
period that the virus circulates.
3 Age distribution of cases
The age distribution of cases reflects the distribution of
immunity in a population at the start of an outbreak, with a
higher average age of cases being consistent with a lower crude
prevalence of infection immunity, and thus with more extensive
(and more rapid) virus spread.
The relationship between the average age of cases (and infected
contacts), and the extent of spread is complicated. The case-to-
infection ratio of wild poliovirus is age-dependent, with a higher
number of infections per case among younger persons[28,29],
which means that the age distribution of disease may not closely
mirror the age distribution of infection. Furthermore, although
poor hygiene practices conducive to VDPV spread may be most
common among young children, older children are likely to travel
further, and contact a broader range of individuals, resulting in
higher rates of effective contact.
4 Outbreak ascertainment and response
The greater the delay between illness onset in the index case,
and the initiation of response activities, the more widespread virus
circulation is likely to be. Similarly, extensive and high-quality
responses are consistent with shorter transmission duration and
reduced geographic spread compared to circumstances in which
the outbreak responses are of poorer quality.
5 Surveillance data
In a polio-free area, the minimum annual expected AFP rate is
at least 1 per 100,000 population aged under 15 years. Data on
the completeness of AFP reporting and case investigation
(including the proportion of AFP cases from whom two adequate
stool specimens are obtained) are collected in many countries.
Data on the likely efficiency of AFP case detection prior to and
during an outbreak can be used to infer what proportion of cases
may have been missed. The extent and results of additional
surveillanceactivitiesconductedduringVDPVcirculation,including
environmental sampling, community stool surveys, and (retrospec-
tive and active) case searches provide information on the extent of
VDPVtransmissioninthecommunity.Extensivesamplingwithonly
negative results suggests limited transmission, whereas poor
surveillance is at least consistent with widespread infection
transmission.
6 Social characteristics of cases
The extent of VDPV spread will vary between populations.
Cases from disparate social groups suggest wider circulation than
those occurring within the same population subgroup. Population
mobility will influence the geographic extent of virus spread.
cVDPV isolates identified in crowded populations and/or those
with poor hygiene suggest more extensive transmission compared
with those found among socially privileged populations. Similarly,
populations with a high annual growthrate (particularlywhere thisis
determined principally by a high birth rate) will be more prone to
extensive VDPV circulation in the absence of high and continuous
levels of vaccination coverage, due to the relatively high proportion
of new susceptibles being introduced into the population.
7DivergenceofVDPVisolatesfromthereferenceOPVstrain
Polioviruses evolve at an annual rate of approximately 1% of
nucleotide substitutions per site in the VP1 gene[1–4,30–32].
Thus, sequencing the VP1 region enables a rough estimate of the
duration of VDPV circulation. The cumulative number of
infections will increase with time and thus the greater the (average)
number of nucleotide substitutions of prevalent viruses, the greater
the implied extent of (prior) infection transmission.
8 Degree of genetic diversity among VDPV isolates
The extent of genetic diversity among isolates provides
information on the patterns of poliovirus transmission. In areas
with sensitive surveillance, low genetic diversity among contem-
porary isolates is consistent with narrow chains of transmission
with limited branching, whereas high diversity follows early and
potentially extensive branching of the chains of transmission. High
diversity implies prolonged circulation in populations with large
immunity gaps.
9 Type-specific properties of VDPVs
OPV viruses and their wild parent strains vary by type in their
relative transmissibility and virulence. For OPV, transmissibility
and virulence are in the order of 2.1,3[33] and 3.2.1[34]
respectively. For WPV, transmissibility is clearly higher than for
OPV strains, and probably roughly equal among types, though
there is some evidence that type 1 may be more transmissible than
types 2 or 3[35]. In terms of virulence, the case-to-infection ratios
for wild viruses appear to be greatest for type 1 (,1:200) and
lowest for types 2 and 3 (,1:1000)[36,37]. Attenuation of Sabin
strains is based on few nucleotide substitutions for types 2 and 3,
with more for type 1[38–41]; thus type 2 or 3 Sabin strains may be
expected to revert more rapidly than type 1.
10 Case-to-infection ratio
The estimated occurrence of 0.36–1.92 cases of VAPP per
million initial doses of OPV administered [34,42–46] provides an
indication of the virulence of Sabin-derived viruses (immediately
or very soon) following vaccine administration. During the course
of serial transmission, their virulence is expected to increase by
genetic reversion towards 1:200 (for type 1) or 1:1000 (for types 2
and 3), although the rate at which this occurs is unknown. The
genetic changes associated with more efficient replication in the
intestine are also associated with increased neurovirulence, and
probably also contribute to more efficient transmissibilities because
of higher yields of excreted virus[47]. Thus, given the number of
paralytic cases caused by a cVDPV, we can estimate (albeit within
a broad range) the number of individuals that may have been
infected. The lower the case-to-infection ratio, then the greater the
implied extent of infection transmission for a given observed (or
inferred) number of cases. This inference also needs to consider
that the case-to-infection ratio may vary by age[28,29].
Results
1 Hispaniola
The first recognized cVDPV outbreak occurred on Hispaniola
resulting in 21 VC and 21 polio-compatible (PC) cases reported in
2000–1[12,48] (figure 1).
1.1 Space-time pattern. Although fewer cases were reported
in Haiti (8 VC and 4 PC) than in the Dominican Republic (DR)
(13 VC and 17 PC), the Haiti cases occurred over a longer
duration of time (1 year versus 6 months) suggesting that
transmission there was more widespread. Cases were reported
from a greater number of departments in the DR than in Haiti (5
versus 3), but this may reflect poor case ascertainment in Haiti,
rather than more localized spread of infection.
Estimating VDPV Spread
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with wild poliovirus was in 1985 in the DR and in 1989 in Haiti,
suggesting that ‘‘naturally-induced’’ immunity to infection was
restricted to adults over 15 and 11 years of age in the two
countries respectively.
NIDs were conducted in DR between 1983 and 1995 and
reported routine OPV3 coverage was ,80% nationally for over a
decade prior to the outbreak (although coverage was as low as
20% in outbreak communities). This implies that by 2000,
susceptibles were concentrated among the under fives (total
,1.2 million), of whom approximately (120.8)61,200,000=
240,000 children ,5 years old were unvaccinated when the
outbreak occurred. It is likely that at least 200,000 were susceptible
to infection.
In Haiti, the prevalence of immunity was probably much lower,
with reported national OPV3 coverage fluctuating between 30%
and 58% between 1989 and 1999 (but as low as 7% in some
communities), and no history of NIDs. This is consistent with up to
70% of children ,11 years of age being susceptible to infection
when the outbreak occurred, or around 1,600,000 children
(0.7062,300,000).
1.3 The age distribution of cases. The median age of the
virologically-confirmed cases was higher in Haiti than in the DR
(7 years [range: 2–12 years] versus 3 years [range:9 months–
14 years]), reflecting differences in the age distribution of
immunity to infection between the two countries. This age
difference is consistent with more extensive infection spread in
Haiti relative to the DR, both because a greater proportion of the
population was susceptible to infection, and also because a broader
age range of infected people is likely to correspond to a broader
range in contact patterns between infected and susceptible
individuals.
1.4 Ascertainment and response. In the DR, three OPV
campaigns were initiated: 5, 7 and 9 months after paralysis onset
in the index case (see figure 2), resulting in close to 100% coverage
of all children ,5 years. The last known case had onset shortly
after the first round, suggesting that the response was sufficient to
prevent further transmission of the outbreak strain. By contrast,
the first two rounds of vaccination at fixed posts in Haiti in early
2001 resulted in less than 40% coverage of the target population,
and cases continued to occur. The house-to-house campaign
conducted in mid-2001 coincided with the last clinical case and
apparent interruption of cVDPV transmission.
1.5 Surveillance data. AFP surveillance performance
indicators declined prior to the outbreak. By 1999, the non-polio
AFP rate per 100,000 population aged under 15 years was 0.3 in
the DR and 0.12 in Haiti, with adequate stool samples taken from
only 30% of AFP cases in the DR and from 0% in Haiti. The
probability that a non-polio AFP case was reported and that
adequate stool samples were taken was therefore only around 0.1
in the DR (0.360.3) and close to 0 in Haiti. As such, it is highly
unlikely that the index cases were the first infected individuals in
either country. However, the fact that the virus in the DR index
case appears close to ancestral to all subsequent DR viruses is
consistent with its being among the earlier infected individuals in
that country. No AFP cases were identified retrospectively.
From 12 July 2000 to 31 July 2001, 123 AFP cases were
reported from the DR, from which 13 (11%) had type 1 cVDPV
isolated. Only 33 AFP cases were investigated during approxi-
mately the same period in Haiti, of which 8 (24%) were associated
with cVDPV. This corresponds to an annual non-polio AFP rate
of 3.8/100,000 in the DR, and ,0.9/100,000 in Haiti. The
difference in the AFP rate in each country and in the proportion
attributed to cVDPV is further evidence that more cases went
unreported in Haiti than in the DR. The poorer AFP
ascertainment in Haiti compared to the DR is consistent with
more widespread transmission on this part of the island.
Sampling among healthy contacts of AFP cases was conducted
in both countries, with 2/36 contacts positive for type 1 cVDPV in
Haiti and 10/205 positive in the DR. Environmental sampling was
conducted at the peak of the outbreak from sewage, canals, and
public latrines in several sites, with 2/12 (17%) samples from Haiti
Figure 1. Geographic distribution of virologically-confirmed cases (represented by grey circles) and polio compatible cases
(represented by filled stars) associated with type 1 cVDPV outbreak in Hispaniola between July 2000 and July 2001. Environmental
samples that were positive for type 1 cVDPV isolates are represented by light grey triangles.
doi:10.1371/journal.pone.0003433.g001
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positive samples came from two urban sites in the DR and one in
Haiti (shown in figure 1), consistent with extensive infection among
these populations (where confirmed polio cases also occurred).
1.6 Social characteristics of cases. Up to five million
Haitians (55% of the population) live in abject poverty, over four
million are without access to safe water and up to three million are
slum-dwellers[50]. Worse living conditions in Haiti relative to the
DR, combined with lower levels of population immunity mean
that VDPV transmission was probably considerably higher than in
the DR.
1.7 Divergence of VDPV isolates from the reference OPV
strain. Characterisation of isolates from the first two reported
cases showed that the outbreak strain had 97.4% and 98.1%
sequence identity to Sabin 1, suggesting that the initiating OPV
dose occurred in late 1998 or early 1999, 18 months before illness
onset in the index case[12]. Assuming an average interval between
infections of 2–4 weeks, this implies 20–40 generations of
transmission occurred prior to the index case.
1.8 Degree of genetic diversity among VDPV
isolates. Sequence analysis of the outbreak isolates suggests
that the initiating dose occurred in Haiti, and was followed by
repeated divergence of the virus lineages[12]. The virus is
estimated to have been introduced into the DR in early 2000, a
few months before illness onset in the index case. The VP1
nucleotide diversity of the Haitian isolates was higher than that of
the Dominican isolates (0.030 versus 0.007 nucleotide differences
per site), consistent with other indicators that transmission was
more widespread, and case ascertainment poorer in Haiti than the
DR.
1.9 Type-specific properties of the cVDPV. The outbreak
strain was derived from Sabin 1, which is the least virulent of the
Sabin strains, and is less transmissible than Sabin 2[51]. Though
the dynamics of VDPV emergence are poorly understood, the low
initial virulence may imply a large number of infections prior to
detection of the first cases.
1.10 Case-to-infection ratio. The first two outbreak isolates
were shown to be highly neurovirulent in a transgenic mouse
model, and replicated to high titres at 39.5uC in cultured cells[12],
suggesting that by July 2001, after approximately 18 months of
circulation, the case-to-infection ratio was likely to have
approached the 1:200 estimated for wild-type 1 virus.
Extent of VDPV infection on Hispaniola
VDPV infection appears to have covered a broader area and
infected many more people in Haiti than in the DR due to the
lower levels of population immunity, poorer sanitation and
hygiene, and a slower response to the outbreak on this part of
the island. The virological evidence suggests that the virus
circulated for over two years in Haiti, and for around nine
months in the DR.
In Haiti, response, surveillance and virological data suggest that
case ascertainment may have been as low as 20%, which is also
consistent with fewer reported cases over a longer time period. A
case-to-infection ratio of 1:200 would suggest that around 12,000
infections (i.e. 12656200=12 cases6under-reporting factor6case-
to-infection ratio), occurred in the outbreak period alone. A case-to-
infection ratio of 1:1000 would imply 60,000 infections. Since the
initiating dose was given in Haiti around 20 months prior to the
onset of paralysis in the index case, in a population containing over
one and a half million susceptibles under 10 years old, it is likely that
the total number of infections was at least 100,000.
Thirty polio cases were reported from the DR between July
2000 and January 2001, with surveillance indicators and
virological data suggesting that case ascertainment was probably
around 50%. If the cVDPV had regained a high degree of
virulence (1:200 case-to-infection ratio) for the entire duration of
its circulation, then this would imply that around 12,000 infections
occurred during this period. It is likely that the average case-to-
infection ratio of the cVDPV was lower than 1:200, and that case
ascertainment was lower than 50% in the early stages of the
outbreak (given the results of the retrospective case search and
surveillance indicators for 1999). If case ascertainment had been
40% and the average case-to-infection ratio in the order of 1:1000,
then the total number of infections in the DR would have been
closer to 75,000.
2 Indonesia
In June 2005, a type 1 cVDPV outbreak began in Indonesia,
resulting in 46 VC cases[11]. A concurrent polio outbreak
Figure 2. (adapted from Fig 1; Kew et al. 2002 Science 296: 356:359)Temporal distribution of virologically-confirmed and compatible
cVDPV cases (grey bars) in Haiti (left hand panel) and in the DR (right hand panel), plotted against the left axis. The estimated number
of infections (dotted lines) between the estimated date of the initiating infection and the end of the outbreak is shown against the right hand axis.
The number and temporal distribution of these infections represents our best estimate, assuming infection peaks during the summer months,
average case ascertainment of 20% in Haiti, and 50% in the DR, and constant case to infection ratios of 1:200 (----) or 1:1000 (- - -). Black arrows
indicate the dates of NIDs, dashed arrows represent sub-optimal NIDs (in Haiti), and the smaller arrows represent the rolling immunisation campaign
in Haiti between May and July 2001.
doi:10.1371/journal.pone.0003433.g002
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same year.
2.1 Space-time pattern. 45/46 virologically-confirmed
cVDPV cases occurred between June and October 2005 on
Madura island, while one case occurred on the neighbouring
island of Java. VDPV cases occurred in all four of Madura’s
districts (and in 16/68 sub-districts), with several distinct clusters
occurring in the rural northern areas of three of the districts
(figure 3), indicating extensive geographic spread of the virus. Ten
polio-compatible cases occurred during the outbreak period in six
sub-districts, with a temporal and geographic distribution
compatible with virologically-confirmed VDPV (figure 3).
2.2 Population immunity. Prior to the co-circulating
outbreaks of WPV and VDPV in 2005, the last case associated
with WPV was reported from Indonesia in 1995, suggesting that
naturally-induced immunity was restricted to individuals
.10 years old in 2005. NIDs were last conducted in 2001,
following which polio immunisation was restricted to routine
vaccination. Data on vaccination coverage from convenience
samples and non-polio AFP cases suggest that immunisation levels
were particularly low in Madura, with over 50% of those ,5 years
of age having received less than 3 doses of OPV.
With approximately 1.2 million children under 10 years old on
Madura island, it is likely that over half a million were susceptible
to infection during the period of cVDPV emergence. Within
Indonesia, the number of susceptible children under 10 years old
is likely to have been over 10 million by 2005.
2.3 The age distribution of cases. The median age of the
45 Madura cVDPV cases was 2 years (range: 6 months to
14 years). 56% (25) of cases were under 3 years old and 20% (9)
were 5 years or over. The broad age distribution of the cases is
consistent with absence of WPV circulation for over a decade and
variable coverage by vaccination services over the same period,
giving rise to the potential for extensive geographic cVDPV
spread.
2.4 Ascertainment and response. Improved surveillance in
Indonesia following the detection of WPV in May 2005 is likely to
have accelerated the confirmation of the index case as cVDPV in
August 2005, within two months of virus isolation.
In response to the detection of WPV cases, NIDs were
conducted in August, September, and November 2005 (figure 4),
with reported coverage .80% in Madura. Illness onset of the last
identified cVDPV case occurred in October, while illness onset in
the last WPV case on Madura occurred in December.
2.5 Surveillance data. AFP performance surveillance
indicators for Madura prior to the recognition of the cVDPV
outbreak were low, consistent with poor case identification and the
potential for widespread virus circulation.
The non-polio AFP rate per 100,000 children ,15 years of age
was 0.4 per year in 2003 and 0.7 in 2004. Adequate stool samples
were collected from 69% of reported cases in 2004, suggesting that
only about half (0.70 * 0.69=0.48) of non-polio AFP cases were
reported and had adequate stool samples collected in the year prior
to recognition of the index case.
The non-polio AFP rate increased to 3.3 per 100,000,15 year
olds during the first half of 2005 when the cVDPV cases were
detected (4/8 reported AFP cases were confirmed as cVDPV
during this period), consistent with poor case ascertainment before
the recognised outbreak period. AFP surveillance performance
was lowest in Sumenep district, which reported the fewest VDPV
cases.
Active searches for AFP cases with paralysis onset in the three
months prior to the index case were conducted in neighborhoods
of confirmed VDPV or WPV cases, and resulted in no further
cases being identified.
2.6 Social characteristics of cases. The majority of the
Madura cases occurred in sub-districts with a population density of
500–1000 persons/km
2, and came from poor, rural households,
with low utilisation of health services, and suboptimal hygiene and
sanitation practices, providing ideal conditions for virus spread.
Figure 3. (adapted from Fig 1; Estivariz et al. 2008 JID 197: 347–354) Geographic distribution of virologically-confirmed and polio-
compatible type 1 cVDPV cases on Madura, Indonesia between June and October 2005. Population density in Madura for 2005 is shown
by district
doi:10.1371/journal.pone.0003433.g003
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strain. Characterisation of outbreak isolates demonstrated a
sequence difference between the outbreak strain and Sabin 1 of
1.1–2.2%, suggesting cVDPV circulation for up to two years prior
to detection of the index case, and implying 26–52 ‘‘generations’’
of transmission during this period.
2.8 Degree of genetic diversity among cVDPV isolates. A
phylogenetic analysis of the isolates showed four distinct lineages
were represented in separate geographic clusters, which were
recombinant with other species C enteroviruses. The hete-
rogeneity among the isolates is consistent with extensive
transmission of the outbreak strain.
2.9 Type-specific properties of the cVDPV. Type 1 is the
least virulent of the Sabin strains, consistent with a large number of
infections prior to identification of the index case.
2.10 Case-to-infection ratio. If the outbreak strain had fully
regained a case-to-infection ratio consistent with wild type 1 when
the cases occurred, and if case ascertainment was complete (46 VC
and 10 PC cases), then the minimum number of infected
individuals during the outbreak might have been as low as
10,000. A lower case-to-infection ratio of 1:1,000 would imply in
the region of 50,000 to 60,000 infections during the outbreak
period.
Extent of VDPV infection in Indonesia
These arguments indicate that the spread of VDPV infection in
the Indonesian outbreak was likely to have been extensive on
Madura Island, and limited on Java. Four distinct lineages of the
outbreak VDPV circulated for up to two years (26–52 ‘‘genera-
tions’’) before transmission was terminated, and were present in all
districts in Madura among subgroups of the population who were
poorly immunised, had not been exposed to WPV circulation for
over a decade and who lived in conditions conducive to poliovirus
spread. Ascertainment is unlikely to have been 100% due to the
reported logistical difficulties encountered during the response
activities and limited retrospective searches for AFP cases. The
apparently later introduction, and relatively limited circulation of
type 1 WPV on the same island, also suggests that immunity levels
to type 1 may have been recently boosted by the circulating VDPV
strain, although vaccination response activities would have limited
WPV spread. Taken together, it is not unreasonable to estimate
that at least 100,000 individuals were infected in Indonesia during
the full period in which the VDPV circulated, with the vast
majority residing on Madura.
3 Egypt
A retrospective analysis of stored poliovirus isolates revealed that
type 2 cVDPV circulated in Egypt between 1988 and 1993[1]. Of
30 isolates from this era initially thought to have been wild type 2,
all proved to be cVDPVs.
3.1 Space-time pattern. The recognised cVDPV cases were
from 7 of the 27 governorates of Egypt, with onset dates between
1988 and 1993 (Figure 5). The predominance in the north reflects
the geographic bias in the collection history of the stored samples.
The 7 governorates contain around 50% of the total population.
3.2 Population immunity. Though the last reported wild
type 2 polio case in Egypt was in 1979, the exact date of
eradication of this serotype is unknown since AFP surveillance
began only in 1990[52]. Wild poliovirus types 1 and 3 circulated in
Egypt throughout the 1990s, with type 1 still present up to 2005
[53]. National vaccination data for the period are incomplete, but
suggest that OPV3 coverage was low but gradually increasing
throughout the 1980s.
There were approximately 20 million children under 15, and
around 1.25 million births per year, in Egypt throughout the
1980s[54] suggesting that millions of individuals were susceptible
to WPV2 infection during the outbreak period.
3.3 Age distribution of cases. Age information is no longer
available on the cases from whom the isolates were obtained.
3.4 Ascertainment and response. There was no specific
response to the outbreak in Egypt as it was ascertained
retrospectively. Transmission is likely to have ceased in the mid-
1990s following an increase in OPV coverage[55].
Figure 4. Temporal distribution of virologically-confirmed
(grey bars) and compatible cVDPV cases (dashed bars) in
Madura, plotted against the left axis. The estimated number of
infections (dotted lines) between the estimated date of the initiating
infection and the end of the outbreak is shown against the right hand
axis. The number and temporal distribution of these infections
represents our best estimate, assuming average case ascertainment of
80%, and constant case to infection ratios of 1:200 (----) or 1:1000 (- - -).
Black arrows indicate the dates of NIDs.
doi:10.1371/journal.pone.0003433.g004
Figure 5. Geographic distribution of virologically-confirmed
type 2 cVDPV cases in Egypt between 1988 and 1993. Individual
cases are represented by filled circles of different sizes to show the year
of paralysis onset. Population density for Egypt in 1990 is shown by
governorate.
doi:10.1371/journal.pone.0003433.g005
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represent only a fraction of those attributable to the cVDPV as
polio surveillance is known to have been poor during the outbreak
period. There was no routine AFP surveillance. The stored isolates
represent cases visiting particular health facilities after 1988.
3.6 Social characteristics of cases. Data on the social
characteristics of the cases have not been reported, but both the
living and sanitary conditions, and the population density (among
the highest in the world) and frequent mixing patterns in Egypt
favour poliovirus spread, as shown by the persistence of wild type 1
until early 2005.
3.7 Genetic divergence of VDPV isolates from the
reference OPV strain. The outbreak isolates had between
93% and 97% nucleotide sequence identity to the Sabin type 2
strain, and a regression analysis of the VP1 evolution rate suggests
that the lineages resulted from an OPV infection that occurred in
about 1983 (95% CI: 07/79–03/86), as shown in figure 6. This
suggests that cVDPV circulated for approximately 5 years prior to
the date of onset of the first stored isolate, and for around 10 years
in total.
3.8 Degree of genetic diversity among VDPV
isolates. Sequence analyses show a high degree of nucleotide
diversity between the outbreak isolates, consistent with multiple,
extensive chains of transmission and incomplete case
ascertainment[1].
3.9 Type-specific properties of the cVDPV. The Egypt
outbreak was associated with type 2 which is the most
transmissible of the Sabin strains[34,51].
3.10 Case-to-infection ratio. The neurovirulence of two
isolates from the outbreak was measured in transgenic mice and
found to be similar to the prototype wild type 2 strain[1].
Assuming a case-to-infection ratio for wild type 2 of 1:1,000, the
30 reported cases alone are likely to be associated with around
30,000 infections (figure 7).
Extent of infection in Egypt
cVDPV infection appears to have been much more extensive in
Egypt than in the other known cVDPV outbreaks, with continued
circulation for approximately 10 years, the occurrence of recog-
nised cases over a broad area that comprised at least 50% of the
total population, and evidence of multiple chains of transmission.
Very high population density, particularly in slum areas in ‘‘mega-
cities’’ and a high birth rate are likely to have contributed to
extensive spread of infection. Virological evidence, along with
poor case reporting before the 1990s, suggest that many hundreds
of cases were probably associated with the outbreak. Taken
together, the evidence indicates that the cVDPV strains became
endemic in the population completely filling the niche vacated by
the disappearance of indigenous wild type 2 viruses. It is likely that
an appreciable proportion (up to several millions) of the
approximately 12 million children born in Egypt 1983–1993 were
infected with these type 2 cVDPV viruses.
Smaller cVDPV outbreaks
In addition to these 3 large cVDPV outbreaks, 5 further
outbreaks of cVDPV have been documented. Table 2 summarises
the findings from applying the same lines of argument to each of
these five settings and shows that between 1,000 and 50,000
individuals were likely to have been infected in each outbreak. The
virological evidence suggests that the extent of infection was likely
to have been particularly limited in the Philippines, with only a few
susceptible pockets in the population likely to have been affected.
In contrast, the data from Madagascar indicate that conditions
were ideal for cVDPV emergence and spread, as confirmed by the
occurrence of two distinct cVDPV strains and a single AFP case
attributable to VDPV[10,13].
Single VDPV isolate episodes
In addition to these multi-case outbreaks, there have been at
least 35 isolations of VDPV strains which appear, because of VP1
divergence ranging from around 1–3%, to have circulated in
populations for periods of ,1–3 years [5–7,14–20,56,57]. These
isolates include 10 derived from type1, 19 from type 2 and 6 from
type 3, and have been identified in more than 20 countries over
Figure 6. (From: Yang et al, J Virol 2003; 77:8366–8377) Estimate
of the date of initiating OPV dose from the rate of accumu-
lation of synonymous substitutions into VP1 among the 28
type 2 cVDPV isolates for which the dates of sample collection
are known. Abscissa: date of sample collection for each isolate.
Ordinate: Ks, the number of substitutions (Sabin 2 sequence set to zero
substitutions) at synonymous sites in VP1. The evolution rate was
estimated by weighted linear regression. The 95% CI for the estimated
date of the initiating OPV dose, July 1979 to March 1986, is bounded by
parentheses along the abscissa.
doi:10.1371/journal.pone.0003433.g006
Figure 7. The distribution of reported cVDPV cases in Egypt
(grey bars) is shown on the left hand axis. The estimated number
of infections (dotted line) between 1983 (when the initiating infection is
estimated to have occurred) and the end of the outbreak is plotted
against the right hand axis, and represents a best estimate of the
distribution of infections. The approximation for the number of
infections is represented by the area under the curve, and assumes a
constant case to infection ratio of 1:1000, and average case
ascertainment of ,10%.
doi:10.1371/journal.pone.0003433.g007
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many individuals may have been infected with any of these VDPV
lineages, 100 is a minimum, but 1000 a more likely low-end
estimate, given their estimated duration of circulation and the
estimated annual number of generations of transmission.
iVDPVs
The long-term excretion of VDPV by some immunodeficient
individuals (iVDPV) has been recognized since 1962[58].
Characterization of some of these isolates suggest that, like
cVDPV, the annual rate of nucleotide substitution in VP1 is
around 1%[30,31], with chronic infection being observed for over
10 years in some cases[59,60]. To date, 40 individuals with
prolonged iVDPV infection have been identified[7,14,56] and
(probable) iVDPV isolates from environmental sampling have
been identified in several settings[7,18–20]. So far, most cases and
isolates have been identified in high- or middle-income commu-
nities, where high levels of immunization and good hygiene and
sanitation standards serve to minimize the risk of spread.
However, there has been one documented episode of iVDPV
spread in the US, among the Amish population who often refuse
OPV, with 5 infections including an immunodeficient child with
long-term VDPV excretion[61].
Discussion
Person-to-person transmission of VDPV infection for pro-
longed periods has been recognised in several settings, and has
resulted in eight fully documented multi-case outbreaks of polio.
In addition, over forty VDPVs have been isolated from
individual AFP cases, healthy individuals, immunodeficient
individuals and in environmental samples in other settings.
The important risk factors for cVDPV emergence-low preva-
lence of immunity to poliovirus infection, low OPV coverage and
poor sanitation-are likely to exist in populations where case
ascertainment is incomplete. It is thus likely that the number of
cVDPV cases recognised in these eight outbreaks falls well below
the true number of cases, particularly in Egypt and Haiti, with
the actual incidence of VDPV-attributable paralytic disease
likely to have numbered in the many hundreds.
The spread of VDPV infection was most extensive in Egypt,
where several million individuals may have been infected by type
2 cVDPV which became endemic following the disappearance,
of indigenous wild type 2 virus. In Hispaniola and Indonesia, at
least 100,000 individuals are likely to have been infected in each
setting, while up to 10,000 infections may have occurred in each
of the five smaller outbreaks. The isolates from single AFP cases,
healthy contacts and environmental samples identified in other
episodes, are together likely to correspond to several thousand
infections. A large type 2 VDPV outbreak is currently ongoing,
with roughly 130 cases attributed to the independent emergence
of seven cVDPV lineages in northern Nigeria [14], where
routine trivalent OPV coverage is ,30%, and most supplemen-
tary immunisation activities have largely used type 1 and 3
monovalent OPV. It is likely that many tens, if not hundreds of
thousands of individuals have already been infected with these
lineages, but the full impact of this ongoing outbreak remains to
be seen.
Each of the eight ‘‘outbreaks’’ ended because of OPV
intervention. In Egypt, this intervention occurred as part of the
scale-up of routine OPV during the 1990s (and one could question
its description as an outbreak, given that the cVDPV had
established itself in the population over a period of several years).
Special NIDs were organised to control the seven other outbreaks.
Reports of cVPDV outbreaks and references to other VDPV
isolates have so far focused on the numbers of clinical cases
involved in these episodes. Their full implications come to light
when the underlying infection incidence is considered. Insofar as
eradication of all poliomyelitis is the PEI target, this will require
total cessation of all poliovirus transmission. To describe the
problem of vaccine-derived polio as 114 virologically-confirmed
cases, worldwide, over some twenty years, gives a very different
impression than a description which suggests a minimum of
hundreds of thousands, and more likely several million infections
by vaccine-derived viruses, some of which became endemic in
large populations. It is also possible that other vaccine-derived
virus lineages have circulated for limited time periods, but failed to
cause any clinical cases and were thus unrecognized[61]. The risk
of VDPV appearance and the incidence and spread of these
infections will be important considerations for policies relating to
the cessation of OPV, for future surveillance needs, and for
planning for outbreak control in the future, including stockpiling
vaccines.
Although the methods developed here give wide-ranging
estimates of the numbers infected during each episode, they
nevertheless highlight the need to focus on the extent of infection
spread in the event of future VDPV episodes. As such, these
methods will become increasingly important for planning
surveillance, control and response activities in the current and
future stages of the eradication programme, as attention focuses
towards reducing cases, and ultimately infections, to zero.
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